Antioxidant < Antiparkinson agent < Antipsychotic

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 23.
[0-20] [0 - 20][0 - 23][20-22][20-40]

Ident.	Authors (with country if any)	Title
000037 (2009)	C Olanow [États-Unis] ; Olivier Rascol [France] ; Robert Hauser [États-Unis] ; Paul Feigin [Israël] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; William Langston [États-Unis] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
000058 (2007)	Joseph Jankovic [États-Unis] ; Mark Stacy [États-Unis]	Medical management of levodopa-associated motor complications in patients with parkinson's disease
000111 (2002)	M Ulivelli [Italie] ; S Rossi [Italie] ; C Lombardi [Italie] ; S Bartalini [Italie] ; R Rocchi [Italie] ; F Giannini [Italie] ; S Passero [Italie] ; N Battistini [Italie] ; E Lugaresi [Italie] ; David Rye [Italie] ; Joseph Jankovic [Italie]	Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Editorial
000114 (2002)	Joseph Jankovic [États-Unis]	Levodopa strengths and weaknesses
000119 (2001)		50th anniversary reprint collection: Parkinson's disease
000124 (2001)	P Hanna [États-Unis] ; L Ratkos [États-Unis] ; W Ondo [États-Unis] ; J Jankovic [États-Unis]	Switching from pergolide to pramipexole in patients with Parkinson's disease
000129 (2001)	Lewis Doshay [États-Unis] ; Kate Constable	Newer drugs in the treatment of parkinsonism
000130 (2001)	Y Agid [France]	Levodopa: Is toxicity a myth?
000135 (2001)	N Giladi [États-Unis] ; M Mcdermott [États-Unis] ; S Fahn [États-Unis] ; S Przedborski [États-Unis] ; J Jankovic [États-Unis] ; M Stern [États-Unis] ; C Tanner [États-Unis]	Freezing of gait in PD: Prospective assessment in the datatop cohort
000137 (2001)	V Fraix [France] ; P Pollak ; N Van ; J Xie ; P Krack [Allemagne] ; A Koudsie ; A Benabid	Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease
000138 (2001)	S Boyce [Royaume-Uni] ; N Rupniak [Royaume-Uni] ; M Steventon [Royaume-Uni] ; S Iversen [Royaume-Uni]	Differential effects of D1 and D2 agonists in MPTP-treated primates: Functional implications for Parkinson's disease
000147 (2001)	Wei Le [États-Unis] ; Joseph Jankovic [États-Unis]	Are dopamine receptor agonists neuroprotective in Parkinson's disease?
000153 (2000)	L Zou [États-Unis] ; JING XU [États-Unis] ; J Jankovic [États-Unis] ; YI HE [États-Unis] ; S Appel [États-Unis] ; W Le [États-Unis]	Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice
000156 (2000)	Joseph Jankovic [États-Unis]	Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients
000161 (2000)	Joseph Jankovic [États-Unis]	Complications and limitations of drug therapy for Parkinson's disease
000165 (1999)	J Jankovic [États-Unis]	New and emerging therapies for Parkinson disease
000168 (1999)	J Jankovic [États-Unis] ; E Lai [États-Unis] ; L Ben [États-Unis] ; J Krauss [États-Unis] ; R Grossman [États-Unis]	Levodopa-induced dyskinesias treated by pallidotomy
000170 (1999)	W Ondo [États-Unis] ; C Hunter [États-Unis] ; M Almaguer [États-Unis] ; S Gancher [États-Unis] ; J Jankovic [États-Unis]	Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease
000171 (1999)	W Le [États-Unis] ; D Rowe [États-Unis] ; J Jankovic [États-Unis] ; WENJIE XIE [États-Unis] ; S Appel [États-Unis]	Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells
000182 (1997)	J Krauss [États-Unis] ; J Jankovic [États-Unis] ; E Lai [États-Unis] ; G Rettig [États-Unis] ; R Grossman [États-Unis]	Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism
000190 (1995)	M Mcdermott [États-Unis] ; J Jankovic ; J Carter ; S Fahn ; S Gauthier ; C Goetz ; L Golbe ; W Koller ; A Lang ; C Olanow ; I Shoulson ; M Stern ; C Tanner ; W Weiner	Factors predicitive of the need for levodopa therapy in early, untreated Parkinson's disease

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PascalFrancis/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/KwdEn.i -k "Antiparkinson agent" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/KwdEn.i  \
                -Sk "Antiparkinson agent" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antiparkinson agent
}}

---

This area was generated with Dilib version V0.6.19. Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024